NEW YORK, Dec. 8 Reportlinker.com announces that a new market research report is available in its catalogue:
Radiopharmaceuticals - A US and European Market Analysis
Advertisement
http://www.reportlinker.com/p0164273/Radiopharmaceuticals---A-US-and-European-Market-Analysis.html
The market for radiopharmaceuticals continues to gain momentum with heightened interest in therapeutic efficiency, acceptance and utilization of nuclear medicine equipment, as well as development of newer diagnostic and therapeutic agents. Besides oncology applications, the nuclear medicine field is presently exploring the possibility of extending the scope and functionality of radiopharmaceuticals to other disease applications such as infection imaging, nephrology and neurology applications. Advancements in nuclear medicine technology would represent a key strategic factor in opening up new clinical opportunities for radiopharmaceutical agents.
Advertisement
These and other market data and trends are presented in "Radiopharmaceuticals: A US and European Market Analysis" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.
RADIOPHARMACEUTICALS BMR-1073
CONTENTS
1. METHODOLOGY 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Quantitative Techniques & Reporting Level 3
2. GLOBAL MARKET OVERVIEW 3
A Quick Primer 3
Key Market Trends 4
Continuous Battle Against Cancer: A Key Driver for Growth 4
Cancer Statistics: A Grim Prognosis 4
Business Case for Radiopharmaceuticals Exemplified 4
Development of Newer Diagnostic Agents to Boost Growth 5
Demographics & New Applications Offer Opportunities On a Platter 5
Recognition of Intrinsic Cost Benefits: Critical to Market
Acceptance 5
Widespread Awareness Among Practitioners & Patients: The Need
of the Hour 6
Expansion of Molecular Imaging Platform is Key to Future Growth 6
Molecular Imaging Agents: A Noteworthy Breakthrough 7
Growing Demand for PET to Drive Up Demand 7
Introduction of SPECT/CT & PET/CT: Double Edged Weapons for
Growth 8
Manufacturers Quick to Take Cue 8
Promising Developments in Therapeutic Radiopharmaceuticals
Underway 9
Targeted Peptides & Alpha Emitters: The New Frontiers of
Therapeutic Radiopharmaceuticals 9
International Collaborations Give a Thumbs Up to Drug
Development 10
Market Challenges 10
High Costs of Drug Development Piques Manufacturers 10
Supply Shortages: A Niggling Cause of Concern 10
Price Sensitivity & Competition from Alternatives Limit
Market Potential 11
Lack of Dosage Standards for Pediatric Patients' Limits
Radiopharmaceutical Efficacy 11
Unfounded Fears of Radiation Exposure Hinder Growth 12
Bottlenecks in Developing Markets 12
Market Share Statistics: In Retrospect 12
3. PRODUCT FACTS 13
A. Diagnostic Radiopharmaceuticals 13
B. Therapeutic Radiopharmaceuticals 14
4. REGIONAL MARKET OVERVIEW 15
i. The United States 15
ii. Europe 34
ii(a). France 37
ii(b). Germany 38
ii(c). Italy 39
ii(d). The United Kingdom 40
ii(e). Spain 41
ii(f). Rest of Europe 42
5. RESEARCH & DEVELOPMENT BREAKTHROUGHS 44
Azaya, Texas University Collaborate for Liposomal Radiation
Therapy 44
Pharmacyclics Reveals Phase 1/2 Study of MGd Antibody Targeted
Radiation Therapy 44
Peregrine Explores Potential of Cotara® for Brain Cancer
Treatment 44
Scientists Develop New Manufacturing Technology For Cancer
Diagnostic Radioisotopes 45
Avid Radiopharmaceuticals Exploits ExpIND to Speed AD Drug
Research 45
Scientists Commend Combination Therapy for Follicular Lymphoma
Patients 46
Missouri University Develops New Cancer Radiotherapy Method 46
AGH Researchers Develop New Radioactive Seed Therapy for Lung
Cancer 47
AnazaoHealth® Obtains US Patent for Novel Radiopharmaceutical
Preparations 47
INMAS Develops Ciprofloxacin Radiolabelling Kit 47
6. CORPORATE DEVELOPMENTS 48
Positron Concludes Dose Shield Acquisition 48
Positron Licenses NuView to Sell Imaging Technologies and Dose
Dispensing Devices 48
Bracco Imaging, Marillion Pharmaceuticals to Develop Novel
Cancer Treatment 48
EUSA Pharma Concludes Cytogen Acquisition 48
AMIC, CRS to Co-Produce Indium-111 49
AMIC, MU Partner to Produce Radioisotopes 49
Bracco, Lantheus to Co-Promote CardioGen-82® 49
Cell Therapeutics Submits sBLA for Use of Zevalin® in First-
Line Therapy 49
Covidien Gets FDA Nod for Generic Myocardial Perfusion Imaging
Kit 49
GE Healthcare Gets FDA Nod For New PET/CT Scanner 50
GE Healthcare, Gamma Medica-Ideas Ink Distribution Deal 50
CIS-US Receives FDA Approval for Generic Choletec® Kit 50
Cellectar Obtains Funds for Clinical Trials 50
Lantheus Medical Completes Phase I Study of Novel PET Imaging
Tracer 50
GE Healthcare, Cardinal Health Partner for Myoview(TM) Imaging Agent 51
Avista Capital Partners Acquires Medical Imaging Unit of
Bristol-Myers 51
Siemens Healthcare Opens Two Radiopharmacies in US 51
Cardinal Health Plans to Offer Services to Support PET
Clinical Trials 51
MEDRAD Associates with PETNET to Ingeniously Deliver FDG 52
Triad Isotopes to Build Four Nuclear Pharmacies 52
AREVA, NCI to Develop Cancer-fighting Radiopharmaceuticals 52
Cardinal Health Expands Manufacturing Capabilities for PET
Imaging Agents 52
Jubilant Completes Draxis Acquisition 53
IBA Plans to Acquire CIS BIO 53
Ion Beam Announces Closure of TAEK Financing 53
IBA Receives Approval for New Radiopharmaceutical Production
Facility in UK 54
Ion Beam Partners with Lantheus to Distribute Neurolite®,
Cardiolite® in Europe 54
EIS Eczacibasi to Acquire 50 Percent Stake in Monrol 54
Siemens to Set up Multiple Radiopharmaceutical Facilities in
India 54
Siemens Plans to Establish Its First Molecular Imaging Centre
in India 55
Bayer and FutureChem Enter Radiolabeling Technology Licensing
Agreement 55
Medrad Mounts Intego(TM) PET Infusion System at UPMC 55
IBA Molecular Announces the Launch of Cyclone ® 18 Twin 56
Immunomedics Announces Pre-Clinical Results for its
Combination Radioimmunotherapy 56
Molecular Insight Develops New Radioiodinated Molecules 56
Immunomedics Develops New Antibody for Radioimmunotherapy 56
Triad Acquires Four Radiopharmaceutical Companies 57
Triad Isotopes Acquires Regional Nuclear Pharmacies 57
Triad Isotopes Merges with Diversified Pharmacy Group 57
Molecular Insight Pharmaceuticals Acquires Radiopharmaceutical
Facility In Texas 57
GE Healthcare to Shelf Production of Products with Short-Lived
Radioisotopes 57
Cell Therapeutics Acquires Zevalin® Lymphoma Drug 57
Premier Signs Contracts with Mallinckrodt, Agfa, Berlex 58
ADMD Announces Patent Licensing for Preparing Actinium-225 58
Bayer Schering Exercises Rights to License Avid's 18-F AV1/ZK
Compound 58
Covidien Signs Agreement with BioSynthema for Cancer Treatment
Technology 59
IBA Signs Contract to Supply Cyclone® 30 to Indian DAE 59
MDS Nordion, Ottawa University to Establish Molecular Imaging
Center of Excellence 59
Bracco, ImaRx Ink Cross Licensing Deal 60
GE Healthcare Signs Exclusive Distribution Deal with Draximage 60
DRAXIMAGE, Med Discovery Form Research Collaboration 60
Schering Changes Corporate Identity to Bayer Schering Pharma AG 60
IBA Establishes New Radiopharmaceuticals Production Facility 61
IBA Receives Approval for Production of Radiopharmaceuticals
at UK Facility 61
IBA Establishes Production and R&D Center in Belgium 61
MDS Nordion to Expand Medical Imaging Agent Production in Europe 61
MDS Nordion, Avid Radiopharmaceuticals Ink Collaborative
Agreement 62
MDS Nordion Establishes Centers of Excellence for TheraSphere®
in Europe 62
Peregrine Opens Facility in China 62
GE Healthcare Receives Approval for First Radiopharmacy
Facility in India 62
Peregrine Pharmaceuticals Launches Anti-Cancer Agent in China 63
GE Healthcare Introduces Proton Package For Radiation Therapy
Planning 63
GE Healthcare Expands Definium Series of Digital Radiographic
Products 63
7. MAJOR PLAYERS 64
Actinium Pharmaceuticals, Inc. (US) 64
Advanced Medical Isotope Corporation (US) 64
Alseres Pharmaceuticals, Inc (US) 64
Bayer HealthCare Pharmaceuticals (US) 64
Bio-Nucleonics, Inc. (US) 64
Bracco Diagnostics, Inc. (US) 65
Cardinal Health, Inc (US) 65
Cellectar, LLC. (US) 65
Cell Therapeutics, Inc. (US) 65
Covidien Imaging Solutions (US) 65
Cytogen Corporation (US) 66
Draximage Inc (Canada) 66
GE Healthcare Limited (UK) 66
GlaxoSmithKline Plc (UK) 66
IBA Molecular North America, Inc. (US) 67
Immunomedics, Inc. (US) 67
Kimberly-Clark, Inc. (US) 67
Lantheus Medical Imaging, Inc (US) 67
MDS Nordion (Canada) 68
Molecular Insight Pharmaceuticals, Inc. (US) 68
Peregrine Pharmaceuticals, Inc. (US) 68
PETNET Pharmaceuticals, Inc. (US) 68
Pharmalucence, Inc. (US) 69
Triad Isotopes, Inc. (US) 69
EXHIBITS
Table 1: Percentage Share Breakdown of Leading Medical
Diagnostics Imaging Manufacturer Value Sales in the World -
2003
Table 2: Percentage Revenue Market Shares of Leading
Radiopharmaceutical Medical Diagnostics Manufacturers in the
World - 2003
Table 3: Percentage Share Breakdown of Radioimmunotherapy
Products Manufacturer Value Sales in the World - 2003
Table 4: Breakdown of Diagnostic Radiopharmaceutical Agents
Procedure Volume by Imaging Procedure in the US - 2009
Table 5: Percentage Share Breakdown of Diagnostic
Radiopharmaceutical Agents in the US - 2012
Table 6: Percentage Share Breakdown of SPECT Myocardial
Perfusion Imaging (MPI) Procedure Volume by Imaging Agent in
the US - 2007
Table 7: Percentage Share Breakdown of Non-Cardiology
Diagnostic Radiopharmaceuticals Agent Manufacturer Value Sales
in the US - 2009
Table 8: Installed Base for SPECT and SPECT/CT Scanners in
Units in the North American Diagnostic Radiopharmaceutical
Market for Years 2008, 2010, 2012 & 2014
Table 9: Breakdown of FDG Procedure Volume by Procedure Type -
2009 (In 000s)
Table 10: US FDG Radiopharmacy Market: Number of Doses, Unit
Cost and Number of Nuclear Pharmacies for the Years 2008 &
2012(P)
Table 11: Percentage Share Breakdown of Leading Diagnostics
Radiopharmaceuticals Agents Manufacturer Value Sales in the US -
2007
Table 12: Percentage Share Breakdown of Leading Cardiology
Diagnostic Radiopharmaceutical Agents Manufacturer Value Sales
in the US - 2007
Table 13: Percentage Share Breakdown of Leading Non-Cardiology
Diagnostic Radiopharmaceutical Agents Manufacturer Value Sales
in the US - 2007
Table 14: Percentage Share Breakdown of Therapeutic
Radiopharmaceuticals Manufacturer Value Sales by Key
Radiotherapeutics in the US - 2007
Table 15: Percentage Share Breakdown of Leading Therapeutic
Radiopharmaceutical Agents Manufacturer Value Sales in the US -
2007
Table 16: Percentage Share Breakdown of Leading FDG
Manufacturers by Number of Cyclotrons Operated in the US -
2007
Table 17: Percentage Share Breakdown of Radiopharmaceutical
Bone Palliation Procedures by Key Radiotherapeutics in the US -
2005
Table 18: Percentage Share Breakdown of Leading Diagnostics
Radiopharmaceuticals Manufacturer Value Sales in the US - 2001
Table 19: Percentage Share Breakdown of Leading Cardiology
Diagnostics Radiopharmaceuticals Manufacturer Value Sales in
the US - 2001
Table 20: Percentage Share Breakdown of Leading Therapeutic
Radiopharmaceuticals Manufacturer Value Sales in the US -
2001
Table 21: Percentage Share Breakdown of Leading
Radiopharmaceuticals Manufacturer Value Sales by Diagnostic
Procedures in the US - 2001
Table 22: Percentage Breakdown of Radiopharmacy Market in the
US - 2005
Table 23: Percentage Share Breakdown of Leading
Radiopharmacies Manufacturer Value Sales in the US - 2001
Table 24: Radiopharmaceuticals Market by Segment in the US:
2007-2015 (Sales in US$ Million)
Table 25: Percentage Breakdown of Radiopharmaceuticals Market
by Segment in the US for the Years 2009 & 2012
Table 26: Percentage Share Breakdown of Diagnostic
Radiopharmaceuticals by Imaging Modalities in Europe - 2008 &
2012
Table 27: Radiopharmaceuticals Market by Region in Europe:
2007-2015 (Sales in US$ Million)
Table 28: Percentage Breakdown of Radiopharmaceuticals Market
by Region in Europe for the Years 2009 & 2012
Table 29: Radiopharmaceuticals Market by Segment in Europe:
2007-2015 (Sales in US$ Million)
Table 30: Percentage Breakdown of Radiopharmaceuticals Market
by Segment in Europe for the Years 2009 & 2012
Table 31: Radiopharmaceuticals Market by Segment in France:
2007-2015 (Sales in US$ Million)
Table 32: Percentage Breakdown of Radiopharmaceuticals Market
by Segment in France for the Years 2009 & 2012
Table 33: Radiopharmaceuticals Market by Segment in Germany:
2007-2015 (Sales in US$ Million)
Table 34: Percentage Breakdown of Radiopharmaceuticals Market
by Segment in Germany for the Years 2009 & 2012
Table 35: Radiopharmaceuticals Market by Segment in Italy:
2007-2015 (Sales in US$ Million)
Table 36: Percentage Breakdown of Radiopharmaceuticals Market
by Segment in Italy for the Years 2009 & 2012
Table 37: Radiopharmaceuticals Market by Segment in the UK:
2007-2015 (Sales in US$ Million)
Table 38: Percentage Breakdown of Radiopharmaceuticals Market
by Segment in the UK for the Years 2009 & 2012
Table 39: Radiopharmaceuticals Market by Segment in Spain:
2007-2015 (Sales in US$ Million)
Table 40: Percentage Breakdown of Radiopharmaceuticals Market
by Segment in Spain for the Years 2009 & 2012
Table 41: Radiopharmaceuticals Market by Segment in Rest of
Europe: 2007-2015 (Sales in US$ Million)
Table 42: Percentage Breakdown of Radiopharmaceuticals Market
by Segment in Rest of Europe for the Years 2009 & 2012
COMPANIES PROFILED
To order this report:
Medical Equipment and Supply Industry: Radiopharmaceuticals - A US and European Market Analysis
More Market Research Report
Nicolas BombourgReportlinkerEmail: [email protected]: (805)652-2626Intl: +1 805-652-2626
SOURCE Reportlinker
